Lumos Diagnostics Holdings Limited (ASX:LDX)

Rob Sambursky
President & CEO
Market Cap (AUD): 148.65M
Sector: Unclassified
Last Trade (AUD): 0.96 -0.03 (-3.03%)
Tab Bar

1. About

Lumos Diagnostics Holdings Limited (ASX:LDX) is a fully integrated developer and manufacturer of point-of-care (POC) diagnostic tests. 

Lumos develops and manufactures proprietary and in-licensed POC diagnostic tests for sale through distributors under its Products division, and develops and manufactures POC diagnostic tests for clients under fee-based commercial contracts, through its Commercial Services division. 

Lumos operations are underpinned by its technology platform, which includes patents, know-how, expertise, skills and capabilities for developing lateral flow POC diagnostic tests for different commercial applications and markets, in addition to a range of customisable digital reader formats and digital applications (hardware and software tools) developed by the Company.

In FY20, Lumos launched FebriDx, a POC diagnostic test that rapidly identifies patients with a microbial infection and, if positive, determines if that infection is caused by a virus or bacteria. Lumos has appointed distributors and commenced commercial sales of FebriDx in target markets including the UK, Germany and Canada. 

An initial 510(k) submission for regulatory clearance for FebriDx in the US is currently under review with the US Food and Drug Administration (FDA). Subject to approval from the FDA, Lumos intends to launch the product into the US market.

Lumos is headquartered in Melbourne Australia and has manufacturing facilities in California and Florida in the United States. The business was founded in 2015 by Planet Innovation (Melbourne, Australia) and merged with Florida-based Rapid Pathogen Screening, Inc. in 2019.

2. Business model

3. Strategy

4. Markets

5. Competition

6. History

7. Team

8. Financials

9. Risk